Skip to main content

Table 3 General characteristics of the studies included in the review

From: Cost-effectiveness analysis of XELOX versus XELOX plus bevacizumab for metastatic colorectal cancer in a public hospital school



Type of study

No. patients


Macedo et al. (2012) [7]

To collect current data and evaluate the effect of bevacizumab on first-line therapy, focusing on each backbone regimen; subgroup analysis.

Systematic review


PFS and OS

Hurwitz et al. (2013) [17]

To describe the results of the analysis of RCTs on bevacizumab in mCRC. The analysis pooled individual patient data from these studies, which allowed a more comprehensive examination of efficacy and safety of bevacizumab.

Systematic review


PFS and OS

Saltz et al. (2008) [4]

To evaluate the efficacy and safety of bevacizumab when added to oxaliplatin in first-line therapy (capecitabin plus oxaliplatin [XELOX] or fluorouracil/folinic acid plus oxaliplatin [FOLFOX]) in mCRC patients.



PFS and OS

Tournigand et al. (2004) [12]

To evaluate FOLFIRI and FOLFOX regimens to determine the best sequence (FOLFIRI or FOLFOX first) to treat mCRC patients.



PFS and OS

Van Cutsem et al. (2007) [18]

To compare panitumumab plus supportive care versus supportive care in mCRC patients who had progressed after standard chemotherapy.



PFS and OS

  1. Abbreviations: XELOX Xeloda® and oxaliplatin, FOLFIRI 5-fluorouracil, leucovorin and irinotecan, FOLFOX 5-fluorouracil, leucovorin and oxaliplatin, RCT randomized, clinical trial, mCRC metastatic colorectal cancer, PFS progression free survival, OS overall survival